These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38131617)

  • 1. Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry.
    Herfarth HH; Afzali A; Fischer M; Hudesman D; Abdalla M; McCabe R; Cohen BL; Ungaro RC; Harlan W; Hanson J; Konijeti GG; Polyak S; Ritter T; Salzberg B; Seminerio J; English E; Zhang X; Long MD
    Clin Transl Gastroenterol; 2024 Mar; 15(3):e00669. PubMed ID: 38131617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting.
    Long MD; Afzali A; Fischer M; Hudesman D; Abdalla M; McCabe R; Cohen BL; Ungaro RC; Harlan W; Hanson J; Konijeti G; Polyak S; Ritter T; Salzberg B; Seminerio J; English E; Zhang X; Sharma PP; Herfarth HH
    Inflamm Bowel Dis; 2023 Apr; 29(4):570-578. PubMed ID: 35700276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel.
    Avni-Biron I; Bar-Gil Shitrit A; Koslowsky B; Levartovsky A; Kopylov U; Weisshof R; Aviv Cohen N; Maharshak N; Hovel D; Israeli E; Naftali T; Goren I; Snir Y; Ollech JE; Banai-Eran H; Broitman Y; Sharar-Fischler T; Dotan I; Yanai H
    Dig Liver Dis; 2022 Feb; 54(2):192-197. PubMed ID: 34887214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
    Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ;
    Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
    Honap S; Chee D; Chapman TP; Patel M; Kent AJ; Ray S; Sharma E; Kennedy J; Cripps S; Walsh A; Goodhand JR; Ahmad T; Satsangi J; Irving PM; Kennedy NA;
    J Crohns Colitis; 2020 Oct; 14(10):1385-1393. PubMed ID: 32280965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
    Chiorean M; Daperno M; Lees CW; Bonfanti G; Soudis D; Modesto I; Deuring JJ; Edwards RA
    Adv Ther; 2023 Oct; 40(10):4440-4459. PubMed ID: 37525075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
    Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
    Sands BE; Armuzzi A; Marshall JK; Lindsay JO; Sandborn WJ; Danese S; Panés J; Bressler B; Colombel JF; Lawendy N; Maller E; Zhang H; Chan G; Salese L; Tsilkos K; Marren A; Su C
    Aliment Pharmacol Ther; 2020 Jan; 51(2):271-280. PubMed ID: 31660640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
    Chaparro M; Garre A; Mesonero F; Rodríguez C; Barreiro-de Acosta M; Martínez-Cadilla J; Arroyo MT; Manceñido N; Sierra-Ausín M; Vera-Mendoza I; Casanova MJ; Nos P; González-Muñoza C; Martínez T; Boscá-Watts M; Calafat M; Busquets D; Girona E; Llaó J; Martín-Arranz MD; Piqueras M; Ramos L; Surís G; Bermejo F; Carbajo AY; Casas-Deza D; Fernández-Clotet A; García MJ; Ginard D; Gutiérrez-Casbas A; Hernández L; Lucendo AJ; Márquez L; Merino-Ochoa O; Rancel FJ; Taxonera C; López Sanromán A; Rubio S; Domènech E; Gisbert JP
    J Crohns Colitis; 2021 Jan; 15(1):35-42. PubMed ID: 32969471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib is an effective treatment for moderate to severe ulcerative colitis, and intestinal ultrasound can discriminate response from non-response: a pragmatic prospective real-world study.
    Ollech JE; Eran-Banai H; Goren I; Sharar Fischler T; Avni-Biron I; Snir Y; Broitman Y; Cohen S; Friedenberg A; Pauker MH; Dotan I; Yanai H
    Ann Med; 2024 Dec; 56(1):2358183. PubMed ID: 38813808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
    Straatmijer T; van Gennep S; Duijvestein M; Ponsioen CIJ; Gecse KB; D'Haens GR; Löwenberg M
    Eur J Gastroenterol Hepatol; 2021 Oct; 33(10):1288-1297. PubMed ID: 33405424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program.
    Hudesman DP; Torres J; Salese L; Woolcott JC; Mundayat R; Su C; Mosli MH; Allegretti JR
    Patient; 2023 Mar; 16(2):95-103. PubMed ID: 36336750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore.
    Lee SD; Allegretti JR; Steinwurz F; Connelly SB; Lawendy N; Paulissen J; Gecse KB
    BMC Gastroenterol; 2023 Feb; 23(1):34. PubMed ID: 36755231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
    Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
    BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries.
    Armuzzi A; Hart A; Cappelleri JC; Mammar N; Hur P; Hoskin B; Hennessy F; Milligan G; Dignass A
    BMC Gastroenterol; 2023 Jan; 23(1):17. PubMed ID: 36658481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
    Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y
    Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Tofacitinib for Treatment of Moderate to Severe Active Ulcerative Colitis: First Report from Iran.
    Jameshorani M; Vahedi H; Sadeghi A; Sima AR; Anushiravani A; Nateghi Beige H; Malekzadeh MM; Naserinejad S; Alatab S
    Arch Iran Med; 2021 May; 24(5):354-363. PubMed ID: 34196200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis.
    Ishida N; Miyazu T; Tamura S; Tani S; Yamade M; Iwaizumi M; Hamaya Y; Osawa S; Furuta T; Sugimoto K
    Dig Dis Sci; 2022 Aug; 67(8):3984-3992. PubMed ID: 34460029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience.
    Kotwani P; Terdiman J; Lewin S
    J Crohns Colitis; 2020 Jul; 14(7):1026-1028. PubMed ID: 32020189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib Versus Oral Prednisolone for Induction of Remission in Moderately Active Ulcerative Colitis [ORCHID]: A Prospective, Open-Label, Randomized, Pilot Study.
    Singh A; Midha V; Kaur K; Mahajan R; Singh D; Kaur R; Kohli A; Chawla A; Sood K; Bansal N; Sood A
    J Crohns Colitis; 2024 Feb; 18(2):300-307. PubMed ID: 37656880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.